Estuary Biotherapeutics
Estuary Biotherapeutics develops locally delivered gene therapies for patients with inherited polycystic kidney disease.
$93MSeries A
ParticipantDT
Deep Track Capital
Activity from announced rounds
Activity in this selectionOct 17, 2026 · Jul 20, 2026
Deep Track Capital is a life-sciences investor identified by Draig Therapeutics and Superluminal Medicines.
Recorded funding activity
Superluminal combines structural biology, protein dynamics, machine learning and experiments to discover small-molecule medicines. Draig develops neuropsychiatric treatments, while Triveni works on antibodies for immunological and inflammatory disorders. These company relationships give context to the recorded financings.
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $153M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionSuperluminal Medicines
Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.
$60MSeries B
Participant